MedTrace Logo

Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)

NCT00130195 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2008-11-14

No results posted yet for this study

Summary

The purpose of this study is to determine the clinical efficacy and safety of imatinib-combined chemotherapy on newly diagnosed BCR-ABL-positive ALL.

Conditions

Interventions

DRUG

imatinib

DRUG

cyclophosphamide

DRUG

daunorubicin

DRUG

vincristine

DRUG

prednisolone

DRUG

methotrexate

DRUG

cytarabine

DRUG

dexamethasone

Sponsors & Collaborators

  • Japan Adult Leukemia Study Group

    lead OTHER

Principal Investigators

  • Fumihiko Hayakawa, MD · Nagoya University

  • Tomoki Naoe, MD · Nagoya University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-09-30
Primary Completion
2008-02-29
Completion
2008-05-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00130195 on ClinicalTrials.gov